DELIVERY OF FLUIDS BY THE SUBCUTANEOUS ROUTE

EDITOR,—We would like to contribute to the excellent review by Mbamalu and Banerjee on the principles and problems of peripheral venous cannulation. Although peripheral venous cannulation to allow fluid and electrolyte replacement is mandatory in emergencies and in situations where strict fluid balance is required, it is worth noting that it may not always be feasible. Hypodermoclysis, the technique of correcting fluid deficits by subcutaneous infusion popularised initially in the 1950s, serves as a useful parenteral alternative to intravenous cannulation. Isotonic fluids may be introduced into subcutaneous tissues where the aim is to correct mild to moderate dehydration in elderly patients (especially in a chronic care setting where intravenous access in the infirm and elderly is notoriously difficult), in addition to being a less invasive route of drug administration in palliative management where opioid and anticimetic treatment is frequently warranted. Fluid replacement by the subcutaneous route is relatively safe, easier to initiate, demands less nursing time, is more cost effective than intravenous therapy, causes less discomfort, minimises the risk of intravascular infections, does not immobilise a limb (since it may be given into anterior abdominal tissues), and has been found to be less distressing for patients.1 The use of hyaluronidase in the infused solution augments the rate of fluid uptake and volumes up to 3000 ml can be delivered over 24 hours.2 Evidence suggests that potassium chloride may also be added to the subcutaneous infusion and concentrations up to 34 mmol/l have been given, with the only undesirable effect being that of discomfort at the delivery site.3 The chief technical disadvantages of subcutaneous fluid therapy are local oedema and sepsis at the infusion site, but the reported incidence of the latter is exceedingly low.4 Since the welfare of elderly patients in long term care increasingly represents the core of medical workload in Western populations it follows that hypodermoclysis can be an important parenteral route of fluid administration, and may therefore be incorporated as an additional limb in the instructive algorithm proposed by Mbamalu and Banerjee.

JAGDEEP SINGH GANDHI
George Eliot Hospital NHS Trust, Warwickshire

VINOD PATEL
University of Warwick and Diabetes and Asthma Centre, George Eliot Hospital NHS Trust, College Street, Nuneaton, Warwickshire CV10 7DJ, UK

GANDHI M


HIGH DOSE INTRAVENOUS GLUCAGON IN SEVERE TRICYCLIC POISONING

EDITOR,—I read with interest the case report by Sensky and Olczak describing the use of glucagon in severe tricyclic antidepressant (TCA) poisoning.5 I am surprised that the patient was not treated with sodium bicarbonate and that there was no mention of the pivotal role of alkalisation and sodium loading in the management of TCA poisoning. The cardiac toxicity of TCAs is a consequence of the guanidine and benzamide effects on the sodium channels in the heart.6 These effects can be alleviated by the administration of sodium bicarbonate, which reduces the frequency of ventricular arrhythmias, decreases the prolongation of the QRS interval, and reduces hypotension. These effects have been attributed to the increase in plasma sodium concentration, which competes to reverse the inhibition of the sodium channel by the TCA. Alkalisation changes the ionisation state of TCA which may facilitate uncoupling of the TCA from the sodium channel.7 Alkalosis induced by hyperventilation can also be effective. Their patient was acidic with a pH of 7.29 and with evidence of severe cardiac toxicity. Initial resuscitation of this patient should have included aggressive treatment of the acidosis, administration of sodium bicarbonate. Sodium bicarbonate 1–2 mmol/kg (1–2 mEq/kg of 8.4% solution) intravenously is recommended, followed by further doses to maintain an arterial pH between 7.45 and 7.55. Early intubation and mechanical ventilation is also advised in view of (i) the potential for rapid deterioration in conscious level and risk of gastric aspiration and (ii) the development of a confounding respiratory acidosis, which potentiates any cardiac toxicity.

In my experience, early management with sodium bicarbonate minimises any need for antiarrhythmic or inotropic support.

J M L SCHUSTER-BRUCE
United Bristol Healthcare NHS Trust, Directorate of Anaesthesia, Level 7, Bristol Royal Infirmary, Bristol BS2 8HW, UK

The authors respond.

We appreciate the comments by Drs Gandhi and Patel. The inclusion of hypodermoclysis in the algorithm would certainly be worthwhile and the authors have made a good case for consideration of the procedure.

CEREBRAL VENOUS SINUS THROMBOSIS: HEPARIN OR NOTHING?

EDITOR,—A recent review article in your journal gives the impression that the case for heparinisation of all patients with cerebral venous sinus thrombosis (CVST) is proved,1 but most robust study did not come to this conclusion and its results did not achieve statistical significance.2 Given that CVST has a spectrum of presentations from headache to coma and death, a blanket approach to treatment in the absence of good evidence and continued debate3 does not seem sensible.

M B LEWIS
Department of Neurology, Leed General Infirmary, Great George Street, Leeds LS1 3EX, UK


The authors respond.

I acknowledge Dr Lewis’ comment with respect to the Dutch CVST Study Group trial.1 Nevertheless I feel this study in combination with an earlier study by Einhäupl et al which concluded that intravenous heparin should be first line treatment of CVST. The Dutch trial differed in several points from the German study, which may explain its neutral outcome. They are the altogether smaller number of poor outcomes; the larger proportion of patients with isolated...
intracranial hypertension and hence a much better prognosis anyway; finally a different treatment modality using subcutaneous low molecular weight heparin instead of the intravenous route.

I would agree with Bousser that heparin confers a clinically relevant benefit, justifying the use of this treatment as long as we remain unable to predict the outcome in the individual patient with CVST.


Hepatocellular carcinoma

Editor,—We read with interest the excellent review article on hepatocellular carcinoma.1 However Badvie omits to mention Budd-Chiari syndrome and diabetes among the conditions associated with this disease. The evidence of hepatocellular carcinoma in patients with Budd-Chiari syndrome is high. In a study of Japanese patients with chronic Budd-Chiari syndrome by Okuda and colleagues,2 and commented on by Kashyap and Kashyap,3 an incidence of hepatocellular carcinoma of 6% was found. Lawson et al observed a fourfold increased risk of hepatocellular carcinoma in diabetic patients in a study designed to evaluate the effects of hepatic enzyme inducing drugs.4 A population based cohort of 153 852 diabetic patients also showed a fourfold risk of liver cancer in these patients, which was greater in males compared with females.5 La Vecchia et al in a case-control study reported an odds ratio risk associated with a history of diabetes of 2.3 and felt that in their study population history of diabetes could account for 8% of cases of liver cancer.6 It is difficult to speculate whether the fatty liver of diabetes is the hepatocellular injury that predisposes to hepatocellular carcinoma or whether it is the presence of diabetes that leads to increased susceptibility of the damaged liver to progression to hepatocellular carcinoma.

A S Kashyap
Department of Medicine, Armed Forces Medical College, Pune 411040, India

Surekha Kashyap
Department of Hospital Administration, Armed Forces Medical College, Pune 411040, India


DIARY

Falk Symposia

1/2 October 2000: Non-neoplastic diseases of the anorectum—an interdisciplinary approach (Freiburg, Germany)
3/4 October 2000: Immunosuppression in inflammatory bowel diseases—standards, news, and future trends (Freiburg, Germany)
12/13 October 2000: Biology of bile acids in health and disease (Den Haag, The Netherlands)
4 November 2000: Chronnic bowel diseases—progress and controversies at the turn of the century (Bucharest, Romania)

Columbia University College of Physicians and Surgeons, New York

28–31 July 2000: 10th Annual course. A comprehensive review of movement disorders for the clinical practitioner
30 July–5 August 2000: 5th Annual course. Update and intensive review in internal medicine

Ninth International Symposium on celiac disease

10–13 August 2000: Huntsville, MD, USA
Details: Althea Pusateri, Program Coordinator, University of Maryland School of Medicine, 655 W Baltimore Street, Baltimore, MD 21201, USA (tel: +1 410 706 3957; fax: +1 410 706 3103; http://www.celiaccenter.org).

Royal College of Physicians of Edinburgh

2–15 September 2000: Healthcare for older people—the UK experience (course)
7–8 October 2000: Stroke treatment and service delivery (consensus conference)
Details: Education, Audit, and Research Department, Royal College of Physicians of Edinburgh, 9 Queen Street, Edinburgh EH2 1JQ, UK (tel: +44 (0) 131 225 7324; fax: +44 (0) 131 220 4393; web site: www.rcpe.ac.uk).

Royal College of Physicians of Edinburgh/Scottish Intercollegiate Guidelines Network

3 November 2000: Symposium on clinical effectiveness, clinical guidelines and clinical standards
Details: Mrs Anne Fairbairn, Coordinator for Research and EBM, Royal College of Physicians of Edinburgh, 9 Queen Street, Edinburgh EH2 1JQ, UK (e-mail: a.fairbairn@rcpe.ac.uk).

Imperial College School of Medicine, Division of Paediatrics, Obstetrics and Gynaecology

27 June 2000: Caring for sexuality in health and illness (for healthcare professionals and nurses) jointly with Association of Psychosexual Nursing
29 June–1 July 2000: New horizons in recurrent pregnancy loss
5 July 2000: Bereavement
6–7 July 2000: Advances in obstetric medicine: international meeting of obstetric medicine societies (satellite to ISSHP, Paris)

Columbia University College of Physicians and Surgeons, 630 West 168th Street, Unit 39, New York, NY 10032, USA (tel: +1 212 781 5900; fax: +1 212 781 6047; e-mail: cme@columbia.edu).

St Mark’s Hospital & Academic Institute

16–18 October 2000: Frontiers in colorectal disease (lecture course)
Details: The Administrator, St Mark’s Academic Institute, St Mark’s Hospital, Northwick Park, Harrow, Middx HA1 3UJ (tel: +44 (0) 20 8325 4046/8; fax: +44 (0) 20 8325 4039; e-mail: e.power@ic.ac.uk; web site: www.stmarkshospotal.org.uk)
Cerebral venous sinus thrombosis: heparin or nothing?

M B LEWIS

Postgrad Med J 2000 76: 453
doi: 10.1136/pmj.76.897.453c

Updated information and services can be found at:
http://pmj.bmj.com/content/76/897/453.4

These include:

References
This article cites 5 articles, 4 of which you can access for free at:
http://pmj.bmj.com/content/76/897/453.4#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/